Rocbrutinib Plus R-CHOP Yields High Complete Response Rate in Non-GCB DLBCLByQingqing Cai, MD, PhDNovember 16th 2026Qingqing Cai, MD, PhD, discussed early efficacy data for rocbrutinib plus R-CHOP in untreated non-GCB DLBCL and how they compare with frontMIND at ESMO 2026.